Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
A group of Blackstone-affiliated entities, each listed as 10% owners of Bumble Inc (BMBL), sold 7,469,004 shares of Class A common stock on March 17, 2026, at $3.51 per share, generating $26,246,039 in proceeds. The stock trades at $3.74 and is down about 47% over the past six months. The sale was structured as a post-paid forward to an unaffiliate…
On March 17, 2026, several Blackstone-affiliated investment vehicles collectively sold 7,311,014 shares of Bumble Inc. (NASDAQ: BMBL) Class A common stock for roughly $26.2 million at a single transaction price of $3.51. The disposition occurred while Bumble stock trades modestly higher at $3.74 and follows a 47% decline over the prior six months. …
Seven entities, each identified as 10% owners of Bumble Inc. (NASDAQ: BMBL), sold a combined $26.2 million of Class A Common Stock on March 17, 2026, at $3.51 per share. The sales came as the stock traded at $3.74, modestly above the sale price but down roughly 47% over six months. Bumble reported fiscal Q4 2025 revenue and adjusted EBITDA above co…
Tarsus Pharmaceuticals Chief Human Resources Officer Dianne C. Whitfield disposed of 12,274 shares of company stock between March 17 and March 19, 2026, in three transactions totaling $839,069, according to a Form 4 filing. The disposition was carried out under a mandatory 'sell to cover' provision to satisfy tax withholding on vested Restricted St…
Tarsus Pharmaceuticals (NASDAQ: TARS) General Counsel Bryan Wahl executed three sell-to-cover transactions between March 17 and March 19, 2026, disposing of 12,440 shares for roughly $850,417. The sales were made to satisfy tax-withholding obligations tied to the vesting and settlement of Restricted Stock Units and were required under the company's…
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala sold 13,056 shares of common stock between March 17 and March 19, generating $892,528 in proceeds. The sale was executed to satisfy tax withholding obligations in connection with RSU vesting and was mandated by the issuer's sell-to-cover policy. TARS currently trades near $66.75 and the…
Tarsus Pharmaceuticals COO Neervannan Seshadri sold 11,324 shares of company stock between March 17 and March 19, 2026, realizing $772,443. The transactions, disclosed on a Form 4 filing, were carried out to satisfy tax withholding obligations tied to vesting Restricted Stock Units. The company reported robust fourth-quarter and full-year sales dri…
James J. Savina, General Counsel and Corporate Secretary of Travel & Leisure Co. (NYSE:TNL), sold 31,596 shares on March 17, 2026, for $2,223,726. The transaction leaves Savina with 46,980 shares. Separately, Wyndham Hotels & Resorts announced a dividend increase, a CFO appointment and a $650 million senior notes offering. Citizens raised its price…
Bobak R. Azamian, President, CEO and Board Chair of Tarsus Pharmaceuticals, sold 34,603 shares of common stock between March 17 and March 19, 2026, for about $2.36 million to satisfy tax-withholding on vested restricted stock units. Following the transactions Azamian holds 33,421 shares directly and 857,991 indirectly through a living trust. Tarsus…
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu Lin completed three sales of company stock between March 17 and March 19, 2026, disposing of 1,144 shares for a total of $78,203 to satisfy tax-withholding obligations tied to restricted stock unit vesting. The company recently reported robust fourth-quarter and full-year 2025 product sales…
Telos CORP (NASDAQ:TLS) Executive Vice President and General Counsel Edward Hutchinson Jr. sold 101,623 shares of common stock across March 17 and 18, 2026, generating roughly $408,153 in proceeds. The two transactions reduced his direct holdings to 567,278 shares, with an additional 15,904.64 shares held indirectly through a 401k plan. The insider…
Tarsus Pharmaceuticals Chief Financial Officer and Chief Strategy Officer Jeffrey S Farrow sold 6,430 shares of the company's common stock across three transactions from March 17 to March 19, 2026, raising $439,566. The trades were disclosed on a Form 4 filing and were conducted to cover tax withholding tied to vested Restricted Stock Units under t…
Mara Holdings, Inc. Chief Financial Officer Salman Hassan Khan, acting through the S & N Khan Family Trust, sold 16,000 shares on March 17, 2026, at $9.18 per share, for total proceeds of $146,880. The transaction reduced the trust's indirect holdings to 343,165 shares while Khan continues to directly hold 1,951,284 shares. The sale was carried out…
Kenneth Duda, president and chief technology officer of Arista Networks, sold $4.29 million of company stock on March 17, 2026, across multiple transactions and also exercised options to buy 32,000 shares. The filings show sales by Duda and related trusts at prices near the company’s market price, coming after Arista reported stronger-than-expected…
Thiel Frederick G., Chief Executive Officer of MARA Holdings, Inc. (NASDAQ:MARA), sold 27,505 shares on March 17, 2026, for $252,495 under a Rule 10b5-1 plan adopted May 28, 2025. The transaction leaves him with 4,788,954 shares. The sale occurs against a backdrop of a pronounced six-month share decline and a sharp fourth-quarter earnings miss that…
Wei Lin, Chief Medical Officer of Revolution Medicines Inc (RVMD), sold 2,073 shares on March 17, 2026, for $206,222 under a pre-arranged Rule 10b5-1 plan tied to RSU tax obligations. The trade took place as RVMD shares traded near $99.29 following a 156% gain over the prior year. The company reported a Q4 2025 loss that missed estimates and higher…
Astera Labs Chief Executive Officer Mohan Jitendra sold 157,501 shares of the company's common stock on March 17, 2026, under a pre-arranged 10b5-1 trading plan, generating $20,723,773 in proceeds. The transactions were reported on a Form 4 filing with the Securities and Exchange Commission. The disposition occurred in multiple tranches at prices b…
Stephen Michael Kelsey, Revolution Medicines’ President of Research and Development, sold 4,302 shares on March 17, 2026 under a prearranged Rule 10b5-1 plan to meet tax obligations tied to restricted stock unit vesting. The transaction occurred as the stock trades near its 52-week high and after the company reported a fourth-quarter 2025 loss that…
Revolution Medicines President and CEO Mark A. Goldsmith sold 12,871 shares on March 17, 2026, under a pre-set 10b5-1 plan to cover taxes tied to RSU vesting. The transaction amounted to roughly $1.28 million and occurred while the stock traded close to its 52-week high. The company recently reported a wider net loss for Q4 2025 and retains more ca…
Revolution Medicines Chief Operating Officer Margaret A. Horn executed a planned sale of 4,583 common shares on March 17, 2026, generating $455,918. The transaction occurred as RVMD shares trade close to their 52-week high. The company recently reported a wider quarterly loss driven by elevated R&D spending and has drawn multiple analyst reactions …
Two former FBI special agents have filed an anonymous federal lawsuit in Washington D.C. accusing FBI Director Kash Patel of terminating them last fall because of their limited work on the Arctic Frost investigation into alleged fake electors tied to efforts to overturn the 2020 election. The suit seeks reinstatement and contends the agents’ consti…
A consortium including Pale Fire Capital entities and two individuals purchased 1,602,505 shares of Phreesia, Inc. (NASDAQ: PHR) between March 17 and March 19, 2026, for a total of $18.3 million. The transactions increased the group's holdings to 7,648,829 shares. The activity coincides with Phreesia's recent refinancing of its bridge loan, a produ…
Jeff Cislini, general counsel of Revolution Medicines, sold 2,958 shares of the company's common stock in two trades on March 17 and March 19, 2026, receiving about $291,889. The March 17 sale was executed under a 10b5-1 instruction letter adopted in May 2023 to cover tax obligations from restricted stock unit vesting; the March 19 sale followed a …
Xiaolin Wang, Executive Vice President of Clinical Development at Revolution Medicines, sold 2,010 shares on March 17, 2026, generating proceeds of $199,955. The transaction was carried out under a Rule 10b5-1 trading plan put in place November 17, 2025, to cover taxes from restricted stock unit vesting. The move comes while RVMD shares trade close…
Revolution Medicines CFO Jack Anders sold 2,753 shares on March 17, 2026, generating $273,869 in proceeds under a pre-arranged Rule 10b5-1 plan. The move comes as RVMD shares trade close to their 52-week high after a 156% gain year-over-year. The company reported a wider-than-expected Q4 2025 loss driven by higher research and development and SG&A …
